Search alternatives:
significant advances » significant advantages (Expand Search), significantly advanced (Expand Search), significant advancements (Expand Search)
advances decrease » advanced disease (Expand Search), advanced defense (Expand Search)
mediate decrease » mediated defense (Expand Search)
significant advances » significant advantages (Expand Search), significantly advanced (Expand Search), significant advancements (Expand Search)
advances decrease » advanced disease (Expand Search), advanced defense (Expand Search)
mediate decrease » mediated defense (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”
-
12
-
13
-
14
-
15
Bar graphs showing the means and 95% CI of each retinal layer thickness at each visit.
Published 2025Subjects: -
16
-
17
-
18
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
19
Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.
Published 2025“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”
-
20